| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Albumin-like material in urine
|
Comper, Wayne D.
|
|
|
|
S92 |
p. S65-S66
|
artikel
|
| 2 |
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study
|
Ibsen, Hans
|
|
|
|
S92 |
p. S56-S58
|
artikel
|
| 3 |
Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease
|
Mann, Johannes F.E.
|
|
|
|
S92 |
p. S59-S62
|
artikel
|
| 4 |
Albuminuria as a surrogate marker for drug development: A European Regulatory perspective
|
Calvo, Gonzalo
|
|
|
|
S92 |
p. S126-S127
|
artikel
|
| 5 |
Albuminuria: Marker or target in indigenous populations
|
Hoy, Wendy
|
|
|
|
S92 |
p. S25-S31
|
artikel
|
| 6 |
Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?
|
De Zeeuw, Dick
|
|
|
|
S92 |
p. S2-S6
|
artikel
|
| 7 |
Albuminuria predicting outcome in diabetes: Incidence of microalbuminuria in Asia–Pacific Rim
|
Weir, Matthew R.
|
|
|
|
S92 |
p. S38-S39
|
artikel
|
| 8 |
An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population
|
Verhave, Jacobien C.
|
|
|
|
S92 |
p. S18-S21
|
artikel
|
| 9 |
Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy
|
Jacobsen, Peter
|
|
|
|
S92 |
p. S108-S110
|
artikel
|
| 10 |
Cardiovascular risk in chronic kidney disease
|
Anavekar, Nagesh S.
|
|
|
|
S92 |
p. S11-S15
|
artikel
|
| 11 |
Demographic and epidemiologic transition in the developing world: Role of albuminuria in the early diagnosis and prevention of renal and cardiovascular disease
|
Correa-Rotter, Ricardo
|
|
|
|
S92 |
p. S32-S37
|
artikel
|
| 12 |
Detecting and managing patients with type 2 diabetic kidney disease: Proteinuria and cardiovascular disease
|
Mitch, William E.
|
|
|
|
S92 |
p. S97-S98
|
artikel
|
| 13 |
Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension
|
Segura, Julian
|
|
|
|
S92 |
p. S45-S49
|
artikel
|
| 14 |
Framingham score and microalbuminuria: Combined future targets for primary prevention?
|
Asselbergs, Folkert W.
|
|
|
|
S92 |
p. S111-S114
|
artikel
|
| 15 |
Glomerular filtration of albumin: How small is the sieving coefficient?
|
Deen, William M.
|
|
|
|
S92 |
p. S63-S64
|
artikel
|
| 16 |
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria
|
Palmer, Andrew J.
|
|
|
|
S92 |
p. S118-S120
|
artikel
|
| 17 |
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial
|
Hunsicker, Lawrence G.
|
|
|
|
S92 |
p. S99-S101
|
artikel
|
| 18 |
Inclusion of albumin as a target in therapy guidelines: Guidelines for chronic kidney disease
|
Warnock, David G.
|
|
|
|
S92 |
p. S121-S123
|
artikel
|
| 19 |
Inclusion of albuminuria in hypertension and heart guidelines
|
Bakris, George
|
|
|
|
S92 |
p. S124-S125
|
artikel
|
| 20 |
Introduction
|
De Zeeuw, Dick
|
|
|
|
S92 |
p. S1
|
artikel
|
| 21 |
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy
|
Alexander, Charles M.
|
|
|
|
S92 |
p. S115-S117
|
artikel
|
| 22 |
Mechanism of albuminuria associated with cardiovascular disease and kidney disease
|
Russo, Leileata M.
|
|
|
|
S92 |
p. S67-S68
|
artikel
|
| 23 |
Microalbuminuria, glycemic control, and blood pressure predicting outcome in diabetes type 1 and type 2
|
Mogensen, Carl Erik
|
|
|
|
S92 |
p. S40-S41
|
artikel
|
| 24 |
Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: Further evidence for a link between microalbuminuria and endothelial dysfunction—The Hoorn Study
|
Stehouwer, Coen D.A.
|
|
|
|
S92 |
p. S42-S44
|
artikel
|
| 25 |
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria
|
Anavekar, Nagesh S.
|
|
|
|
S92 |
p. S50-S55
|
artikel
|
| 26 |
Prevalence of albuminuria in Australia: The AusDiab Kidney Study
|
Atkins, Robert C.
|
|
|
|
S92 |
p. S22-S24
|
artikel
|
| 27 |
Proteinuria and hypertensive nephrosclerosis in African Americans
|
Toto, Robert D.
|
|
|
|
S92 |
p. S102-S104
|
artikel
|
| 28 |
Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN)
|
Remuzzi, Giuseppe
|
|
|
|
S92 |
p. S90-S96
|
artikel
|
| 29 |
The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes
|
Forbes, Josephine M.
|
|
|
|
S92 |
p. S105-S107
|
artikel
|
| 30 |
Trends in the incidence of treated end-stage renal failure in The Netherlands: Hope for the future?
|
Gansevoort, Ron T.
|
|
|
|
S92 |
p. S7-S10
|
artikel
|
| 31 |
Which albumin should we measure?
|
Becker, Gavin J.
|
|
|
|
S92 |
p. S16-S17
|
artikel
|
| 32 |
Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC
|
Brinkman, Jacoline W.
|
|
|
|
S92 |
p. S69-S75
|
artikel
|
| 33 |
Why is proteinuria an ominous biomarker of progressive kidney disease?
|
Zandi-Nejad, Kambiz
|
|
|
|
S92 |
p. S76-S89
|
artikel
|
Tijdschrift beschrijving